Biotech stocks reach 52-week highs following financial reports

Several biotechnology and performance beauty stocks reached 52-week highs on September 4, 2026, driven by financial reports and upcoming clinical trial milestones.

Pro-Dex Inc. (PDEX) saw its stock surge over 18% to $77 following the announcement of its fiscal year 2026 results. The company reported a 16% increase in net sales to $77.5 million, resulting in a yearly profit of $13.7 million, up from $9 million in the previous period.

Odyssey Therapeutics Inc. (ODTX) shares rose over 8% to $29.05. The clinical-stage biopharmaceutical company is preparing for Phase 2b monotherapy and Phase 2a combination trials for its lead drug candidate, OD-001, in the second half of 2026. Despite the stock rise, the company reported a 28% widening of its second-quarter net loss to $52.8 million.

Evolus Inc. (EOLS) reached a 52-week high of $9.31 after a 2% increase. The company reported 21% revenue growth for the second quarter, totaling $84.1 million, while reducing its GAAP loss to $4.5 million from $10.2 million the previous year.